Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: Area51 who wrote (5603)	8/20/2018 8:46:10 PM
From: Gary Mohilner	Read Replies (1) \| Respond to of 5665

I'm not concerned about what's happening during the Summer Doldrums usually a slow period for biotechs. I'm investing in cheap January $14 calls. With technical conferences later in the year and the potential for top line data from the Phase 3 Trial for IMGN853, I believe a price of $20 or more is very possible by the time they expire, if that occurs I'll add a lot of share for further money out of pocket if I sell some of the calls to pay for what I'm keeping. With the approval of IMGN853 late next year or in 2020, I believe IMGN's market cap will certainly be no less than half of SGEN's, and might surpass it if SGEN has no further approved drug. SGEN's current market cap is over $11 billion while IMGN's is $1.35 billion, I frankly cannot see why. Gary